M&A Deal Summary |
|
---|---|
Date | 2023-05-10 |
Target | CTI BioPharma |
Sector | Life Science |
Buyer(s) | SOBI |
Deal Type | Add-on Acquisition |
Deal Value | 1.7B USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1939 |
Sector | Life Science |
Employees | 1,772 |
Revenue | 22.1B SEK (2023) |
SOBI is an integrated biopharmaceutical company with an international market presence, developing and commercializing pharmaceuticals for patients with rare diseases. SOBI was founded in 1939 and is headquartered in Solna, Sweden.
DEAL STATS | # |
---|---|
Overall | 4 of 4 |
Sector (Life Science) | 3 of 3 |
Type (Add-on Acquisition) | 4 of 4 |
State (Washington) | 1 of 1 |
Country (United States) | 2 of 2 |
Year (2023) | 1 of 1 |
Size (of disclosed) | 1 of 3 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2019-09-30 |
Dova Pharmaceuticals
Durham, North Carolina, United States Dova Pharmaceuticals, Inc. is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet medical need. Dova Pharmaceuticals was founded in 2016 and is headquartered in Durham, North Carolina. |
Buy | $915M |